Amphastar Pharmaceuticals, Inc.
AMPH· Nasdaq
AMPHAmphastar Pharmaceuticals, Inc.
Filed Mar 1, 2023 · 10-K · 60 days after period end · 0001297184-23-000019
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | $135.02M | $120.89M | $95.92M | $83.38M |
| Net Income | $33.91M | $19.76M | -$6.27M | -$1.03M |
| EPS Diluted | — | — |
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
| — |
| -$0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Mar 1, 2023 · 60 d after period end
